ATP-binding cassette transporter A1: From metabolism to neurodegeneration

Neurobiology of Disease

Volumn 72, Issue Part A, 2014, Pages 13-21

  Koldamova, Radosveta ^a   Fitz, Nicholas F ^a   Lefterov, Iliya ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Abca1; Alzheimer's disease; Amyloid beta; ApoA I; ApoE; Cardiovascular disease; HDL; LXR; RXR

Indexed keywords

ABC TRANSPORTER A1; BEXAROTENE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; NOOTROPIC AGENT; RETINOID X RECEPTOR; RETINOID X RECEPTOR AGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ABCA1 PROTEIN, HUMAN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEGENERATIVE DISEASE; DIABETOGENESIS; DRUG EFFICACY; DRUG SAFETY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; LIPOPROTEIN METABOLISM; LOSS OF FUNCTION MUTATION; METABOLIC DISORDER; MISSENSE MUTATION; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TRANSCRIPTION REGULATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BRAIN; DISEASE MODEL; GENETICS; METABOLISM; MOUSE; RISK FACTOR; TANGIER DISEASE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; ATP BINDING CASSETTE TRANSPORTER 1; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MICE; RISK FACTORS; TANGIER DISEASE;

EID: 84909633153     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.05.007     Document Type: Review

References (139)

1. Aguilar-Salinas C.A., et al. The R230C variant of the ATP binding cassette protein A1 (ABCA1) gene is associated with a decreased response to glyburide therapy in patients with type 2 diabetes mellitus. Metabolism 2013, 62:638-641.
2. Alaupovic P., et al. Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease). Metabolism 1981, 30:805-809.
3. Andersson S., et al. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3857-3862.
4. Bales K.R., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997, 17:263-264.
5. Bien-Ly N., et al. Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 2012, 32:4803-4811.
6. Bochem A.E., et al. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. Eur. Heart J. 2013, 34:286-291.
7. Boehm-Cagan M.D. Reversal of apoE4-driven brain pathology and behavioral deficits by Bexarotene. J. Neurosci. 2014, 34(21):7293-7301. 10.1523/JNEUROSCI.5198-13.2014.
8. Brunham L.R., et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 2007, 13:340-347.
9. Brunham L.R., et al. Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:548-554.
10. Cascorbi I., et al. Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Pharmacogenomics 2013, 14:485-494.
11. Castano E.M., et al. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 1995, 306(Pt 2):599-604.
12. Chu L.W., et al. A novel intronic polymorphism of ABCA1 gene reveals risk for sporadic Alzheimer's disease in Chinese. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:1007-1013.
13. Clee S.M., et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J. Clin. Invest. 2000, 106:1263-1270.
14. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
15. Cramer P.E., et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
16. Cruchaga C., et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum. Mol. Genet. 2012, 21:4558-4571.
17. Dias I.H., et al. Plasma levels of HDL and carotenoids are lower in dementia patients with vascular comorbidities. J. Alzheimers Dis. 2014, 40(2):399-408. 10.3233/JAD-131964.
18. Dietschy J.M., Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 2001, 12:105-112.
19. Donkin J.J., et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J. Biol. Chem. 2010, 285:34144-34154.
20. Fitz N.F., et al. Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J. Neurosci. 2010, 30:6862-6872.
21. Fitz N.F., et al. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J. Neurosci. 2012, 32:13125-13136.
22. Fitz N.F., et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924-c.
23. Fitz N.F., et al. Improvement of memory deficits and amyloid-beta clearance in aged APP23 mice treated with a combination of anti-amyloid-beta antibody and LXR agonist. J. Alzheimers Dis. 2014, 41(2):535-549. 10.3233/JAD-132789.
24. Frikke-Schmidt R. Genetic variation in ABCA1 and risk of cardiovascular disease. Atherosclerosis 2011, 218:281-282.
25. Frikke-Schmidt R., et al. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J. Clin. Invest. 2004, 114:1343-1353.
26. Frikke-Schmidt R., et al. Mutation in ABCA1 predicted risk of ischemic heart disease in the Copenhagen City Heart Study Population. J. Am. Coll. Cardiol. 2005, 46:1516-1520.
27. Frikke-Schmidt R., et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008, 299:2524-2532.
28. Gelissen I.C., et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler. Thromb. Vasc. Biol. 2006, 26:534-540.
29. Gosselet F., Saint-Pol J., Fenart L. Effects of oxysterols on the blood-brain barrier: implications for Alzheimer's disease. Biochem. Biophys. Res. Commun. 2014, 446(3):687-691. (Epub 2013 Nov 22). 10.1016/j.bbrc.2013.11.059.
30. Gupta V.B., et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 2011, 76:1091-1098.
31. Hanson A.J., et al. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol. 2013, 70:972-980.
32. Harold D., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
33. Hashimoto T., et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J. Neurosci. 2012, 32:15181-15192.
34. Hirsch-Reinshagen V., et al. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 2004, 279:41197-41207.
35. Hirsch-Reinshagen V., et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 2005, 280:43243-43256.
36. Ho Hong S., et al. Novel ABCA1 compound variant associated with HDL cholesterol deficiency. Biochim. Biophys. Acta 2002, 1587:60-64.
37. Hobbs H.H., Rader D.J. ABC1: connecting yellow tonsils, neuropathy, and very low HDL. J. Clin. Invest. 1999, 104:1015-1017.
38. Hovingh G.K., et al. HDL deficiency and atherosclerosis: lessons from Tangier disease. J. Intern. Med. 2004, 255:299-301.
39. Hughes T.M., et al. Markers of cholesterol transport are associated with amyloid deposition in the brain. Neurobiol. Aging 2014, 35:802-807.
40. Jiang Q., et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
41. Jiang M., et al. Meta-analysis on association between the ATP-binding cassette transporter A1 gene (ABCA1) and Alzheimer's disease. Gene 2012, 510:147-153.
42. Jones L., et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE 2010, 5:e13950.
43. Kanekiyo T., et al. ApoE and Abeta in Alzheimer's disease: accidental encounters or partners?. Neuron 2014, 81:740-754.
44. Karasinska J.M., et al. Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J. Neurosci. 2009, 29:3579-3589.
45. Katz A., et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J. Clin. Pharmacol. 2009, 49:643-649.
46. Katzov H., et al. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum. Mutat. 2004, 23:358-367.
47. Khorram Khorshid H.R., et al. The association between sporadic Alzheimer's disease and the human ABCA1 and APOE gene polymorphisms in Iranian population. Iran. Red Crescent Med. J. 2011, 13:256-262.
48. Kim W.S., et al. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J. Biol. Chem. 2007, 282:2851-2861.
49. Kim H.J., et al. Liver X receptor beta (LXRbeta): a link between beta-sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2094-2099.
50. Kim J., et al. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
51. Kim J., et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J. Neurosci. 2011, 31:18007-18012.
52. Koch S., et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J. Lipid Res. 2001, 42:1143-1151.
53. Koldamova R.P., et al. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 2001, 40:3553-3560.
54. Koldamova R.P., et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J. Biol. Chem. 2003, 278:13244-13256.
55. Koldamova R., et al. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 2005, 280:43224-43235.
56. Koldamova R.P., et al. The liver X receptor ligand T0901317 decreases amyloid {beta} production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 2005, 280:4079-4088.
57. Koldamova R., Fitz N.F., Lefterov I. The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration. Biochim. Biophys. Acta 2010, 1801(8):824-830. (Epub 2010 Feb 24). 10.1016/j.bbalip.2010.02.010.
58. Koseki M., et al. Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J. Atheroscler. Thromb. 2009, 16:292-296.
59. Koudinov A.R., et al. Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin. Chim. Acta 1998, 270:75-84.
60. LaClair K.D., et al. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol. Neurodegener. 2013, 8:18.
61. LaDu M.J., et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 1994, 269:23403-23406.
62. LaDu M.J., et al. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J. Biol. Chem. 1995, 270:9039-9042.
63. LaDu M.J., et al. Preferential interactions between ApoE-containing lipoproteins and Abeta revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift. Biochim. Biophys. Acta 2012, 1821:295-302.
64. Lambert J.C., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
65. Lefterov I., et al. Memory deficits in APP23/Abca1+/- mice correlate with the level of Abeta oligomers. ASN Neuro. 2009, 1.
66. Lerner V., et al. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. Clin. Neuropharmacol. 2008, 31:25-33.
67. Lerner V., et al. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial. J. Clin. Psychiatry 2013, 74:1224-1232.
68. Lilley J.S., et al. Oral retinoids and plasma lipids. Dermatol. Ther. 2013, 26:404-410.
69. Lund-Katz S., Phillips M.C. High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell. Biochem. 2010, 51:183-227.
70. Lupton M.K., et al. The role of ABCA1 gene sequence variants on risk of Alzheimer's disease. J. Alzheimers Dis. 2014, 38:897-906.
71. Mahley R.W., Huang Y. Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 2012, 76:871-885.
72. Mahley R.W., et al. Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. JAMA 1991, 265:78-83.
73. McFarland K., et al. Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. ACS Chem. Neurosci. 2013, 4:1430-1438.
74. McNeish J., et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4245-4250.
75. Merched A., et al. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 2000, 21:27-30.
76. Nagata K.O., et al. ABCA1 dimer-monomer interconversion during HDL generation revealed by single-molecule imaging. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5034-5039.
77. Oram J.F., Vaughan A.M. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ. Res. 2006, 99:1031-1043.
78. Panzenboeck U., et al. ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J. Biol. Chem. 2002, 277:42781-42789.
79. Pervaiz M.A., et al. A non-classical presentation of Tangier disease with three ABCA1 mutations. JIMD Rep. 2012, 4:109-111.
80. Pfrieger F.W., Barres B.A. Synaptic efficacy enhanced by glial cells in vitro. Science 1997, 277:1684-1687.
81. Pitas R.E., et al. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J. Biol. Chem. 1987, 262:14352-14360.
82. Poirier J., et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342:697-699.
83. Price A.R., et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924-d.
84. Puntoni M., et al. Tangier disease: epidemiology, pathophysiology, and management. Am. J. Cardiovasc. Drugs 2012, 12:303-311.
85. Rader D.J., deGoma E.M. Approach to the patient with extremely low HDL-cholesterol. J. Clin. Endocrinol. Metab. 2012, 97:3399-3407.
86. Reed B., et al. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014, 71:195-200.
87. Reitz C. Dyslipidemia and the risk of Alzheimer's disease. Curr. Atheroscler. Rep. 2013, 15:307.
88. Reynolds C.A., et al. A survey of ABCA1 sequence variation confirms association with dementia. Hum. Mutat. 2009, 30:1348-1354.
89. Riddell D.R., et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 2007, 34:621-628.
90. Ridge P.G., et al. Alzheimer's disease: analyzing the missing heritability. PLoS ONE 2013, 8:e79771.
91. Rodriguez-Rodriguez E., et al. Association of genetic variants of ABCA1 with Alzheimer's disease risk. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:964-968.
92. Saint-Pol J., et al. Brain pericytes ABCA1 expression mediates cholesterol efflux but not cellular amyloid-beta peptide accumulation. J. Alzheimers Dis. 2012, 30:489-503.
93. Santamarina-Fojo S., et al. Regulation and intracellular trafficking of the ABCA1 transporter. J. Lipid Res. 2001, 42:1339-1345.
94. Saunders A.M., Roses A.D. Apolipoprotein E4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease. Stroke 1993, 24:1416-1417.
95. Schou J., et al. ABC transporter genes and risk of type 2 diabetes: a study of 40,000 individuals from the general population. Diabetes Care 2012, 35:2600-2606.
96. Service S.K., et al. Re-sequencing expands our understanding of the phenotypic impact of variants at GWAS loci. PLoS Genet. 2014, 10:e1004147.
97. Shahim P., et al. Plasma amyloid-beta in patients with Tangier disease. J. Alzheimers Dis. 2013, 35:307-312.
98. Shibata N., et al. Association studies of cholesterol metabolism genes (CH25H, ABCA1 and CH24H) in Alzheimer's disease. Neurosci. Lett. 2006, 391:142-146.
99. Simons M., et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6460-6464.
100. Singleton A., Hardy J. A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci. Hum. Mol. Genet. 2011, 20:R158-R162.
101. Strittmatter W.J., et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:8098-8102.
102. Sun Y.M., et al. The polymorphism of the ATP-binding cassette transporter 1 gene modulates Alzheimer disease risk in Chinese Han ethnic population. Am. J. Geriatr. Psychiatry 2012, 20:603-611.
103. Sundar P.D., et al. Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease. Neurobiol. Aging 2007, 28:856-862.
104. Tai L.M., et al. Soluble apoE/Abeta complex: mechanism and therapeutic target for APOE4-induced AD risk. Mol. Neurodegener. 2014, 9:2.
105. Tang C., Oram J.F. The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim. Biophys. Acta 2009, 1791:563-572.
106. Terwel D., et al. Critical role of astroglial apolipoprotein E and liver X receptor-alpha expression for microglial Abeta phagocytosis. J. Neurosci. 2011, 31:7049-7059.
107. Teslovich T.M., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
108. Tesseur I., et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924-e.
109. Timmins J.M., et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 2005, 115:1333-1342.
110. Tontonoz P., Mangelsdorf D.J. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 2003, 17:985-993.
111. van Dam M.J., et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 2002, 359:37-42.
112. Vanmierlo T., et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol. Aging 2011, 32:1262-1272.
113. Vaughan A.M., Oram J.F. ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J. Lipid Res. 2003, 44:1373-1380.
114. Vedhachalam C., et al. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J. Biol. Chem. 2007, 282:25123-25130.
115. Veeraraghavalu K., et al. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013, 340:924-f.
116. Vergeer M., et al. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 2010, 33:869-874.
117. Verghese P.B., et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E1807-E1816.
118. Villarreal-Molina M.T., et al. Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population. Diabetes 2008, 57:509-513.
119. Wahrle S.E., et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 2004, 279:40987-40993.
120. Wahrle S.E., et al. Deletion of Abca1 increases A{beta} deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 2005, 280:43236-43242.
121. Wahrle S.E., et al. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol. Neurodegener. 2007, 2:7.
122. Wahrle S.E., et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 2008, 118:671-682.
123. Walter M., et al. The high density lipoprotein- and apolipoprotein A-I-induced mobilization of cellular cholesterol is impaired in fibroblasts from Tangier disease subjects. Biochem. Biophys. Res. Commun. 1994, 205:850-856.
124. Walter M., et al. Characterization of atherosclerosis in a patient with familial high-density lipoprotein deficiency. Atherosclerosis 1994, 110:203-208.
125. Wang F., Jia J. Polymorphisms of cholesterol metabolism genes CYP46 and ABCA1 and the risk of sporadic Alzheimer's disease in Chinese. Brain Res. 2007, 1147:34-38.
126. Wang L., et al. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13878-13883.
127. Wang N., et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:9774-9779.
128. Wang X.F., et al. Quantitative assessment of the effect of ABCA1 gene polymorphism on the risk of Alzheimer's disease. Mol. Biol. Rep. 2013, 40:779-785.
129. Wavrant-De Vrieze F., et al. ABCA1 polymorphisms and Alzheimer's disease. Neurosci. Lett. 2007, 416:180-183.
130. Westerterp M., et al. ATP-binding cassette transporters, atherosclerosis, and inflammation. Circ. Res. 2014, 114:157-170.
131. Willer C.J., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 2008, 40:161-169.
132. Wisniewski T., et al. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem. Biophys. Res. Commun. 1993, 192:359-365.
133. Wollmer M.A., et al. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol. Aging 2003, 24:421-426.
134. Wood S.J., et al. An ApoE-Abeta inhibition complex in Abeta fibril extension. Chem. Biol. 1996, 3:949-956.
135. Wood S.J., et al. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 1996, 35:12623-12628.
136. Xiao Z., et al. Association studies of several cholesterol-related genes (ABCA1, CETP and LIPC) with serum lipids and risk of Alzheimer's disease. Lipids Health Dis. 2012, 11:163.
137. Yamanaka M., et al. PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J. Neurosci. 2012, 32:17321-17331.
138. Yu C., et al. Proposed mechanism for lipoprotein remodelling in the brain. Biochim. Biophys. Acta 2010, 1801:819-823.
139. Zelcer N., et al. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver X receptors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10601-10606.